Evidence map›Paper›PMID 40917691›Full record

ArticleMolecular therapy. Methods & clinical development2025

Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior

Patricia Mercier-Letondal, Chrystel Marton, Bernard Royer, Paul Peixoto, Barbara Dehecq, Olivier Adotévi, Jeanne Galaine, Yann Godet

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Patricia Mercier-LetondalUMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.
Chrystel MartonCentre Hospitalier Universitaire de Lille, service des maladies du sang, 59000 Lille, France.
Bernard RoyerCentre Hospitalier Universitaire de Besançon, service de pharmacologie et de toxicologie, 25000 Besançon, France.
Paul PeixotoUMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.
Barbara DehecqUMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.
Olivier AdotéviUMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.
Jeanne GalaineUMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.
Yann GodetUMR 1098 RIGHT INSERM/Etablissement Français du Sang Bourgogne Franche-Comté/Université Marie et Louis Pasteur, 25000 Besançon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the clinical success of redirected T cells in the setting of cancer adoptive cell immunotherapy, patients may exhibit resistance to treatment, resulting in uncontrolled disease and relapses. This phenomenon partly relies on impaired

Indexed as

adoptive immunotherapycytomegalovirusimmune agingnicotinamide adenine dinucleotideredirected T cellsresveratrolT cell differentiation profileT cell fitnessT cell metabolism

Identifiers

PMID40917691
PMCPMC12409381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.